US Prisons Fight Opioids With $1,000 Injections | NBC 5 Dallas-Fort Worth
National & International News
The day’s top national and international news

US Prisons Fight Opioids With $1,000 Injections

Proponents say Vivitrol could save money compared with the cost of locking up a drug offender — about $25,000 a year

    processing...

    NEWSLETTERS

    U.S. prisons are fighting opioid addictions with an experimental drug that critics say are expensive and unproven. (Published Tuesday, Nov. 15, 2016)

    U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials.

    A single shot of Vivitrol, given in the buttocks, lasts for four weeks and eliminates the need for the daily doses common with alternatives such as methadone. But each shot costs as much as $1,000, and because the drug has a limited track record, experts do not agree on how well it works.

    New Artificial Wombs Stimulates Mom for Preemies

    [NATL] New Artificial Wombs Stimulates Mom for Preemies

    A new invention from the Children's Hospital of Philadelphia may soon care for extremely premature babies. Artificial wombs stimulate an environment similar to a mother's womb - a method that researchers say is gentler than ventilators and incubators. 

    (Published 3 hours ago)

    Proponents say Vivitrol could save money compared with the cost of locking up a drug offender — about $25,000 a year for each inmate at the Sheridan Correctional Center, 70 miles southwest of Chicago.

    Dr. Joshua Lee, of New York University's medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it's worth paying for, but the early results are encouraging.

    "It sounds good, and for some of us, it feels like the right thing to do," said Lee, a leading researcher on the treatment.

    Vivitrol is emerging as the nation searches for ways to ease an opioid epidemic that affects more than 2 million Americans and an estimated 15 percent of the U.S. prison population. Many experts view prisons — where addiction's human toll can be seen most clearly — as a natural place to discover what works.

    Teens Overcoming Opioids Seek Treatment in Recovery Schools

    [NATL] Teens Overcoming Opioid Dependence Seek Treatment in 'Recovery Schools'

    A new method for battling teenage opioid abuse comes not in the form of a new drug or counseling method, but in special "recovery schools" that emphasize communal support and positive peer pressure. 

    (Published Tuesday, April 25, 2017)

    Christopher Wolf had already served prison time for nonviolent crimes when he was ordered into treatment for a heroin addiction by a judge who suggested Vivitrol. Three months later, the 36-year-old from Centerville, Ohio, is clean and working full time as a cook.

    He now suggests the medication to other addicts.

    "I don't have cravings," Wolf said. "I see how much better life is. It gets better really fast."

    Vivitrol targets receptors in the brain's reward system, blocking the high and extinguishing urges. In some programs, prisoners get an injection before release, then follow-up shots from any clinic.

    New Orleans to Remove Confederate-Era Monuments

    [NATL] New Orleans to Remove Confederate-Era Monuments

    The city of New Orleans will remove four statues of Confederate-era events and figures in an effort to divorce itself from symbols that some see as problematic. The first statue, the Liberty Place Monument, was taken down early Monday morning. 

    (Published Monday, April 24, 2017)

    For decades, researchers have recognized addiction as a relapsing brain disease with medication an important part of therapy. But most jails and prisons reject methadone and buprenorphine, the other government-approved medications for opioid addiction, because they are habit-forming and can be abused.

    Just ask Joshua Meador, 28, an inmate at Sheridan who hopes to get into the Vivitrol program before his release in January. Before incarceration, he abused both older treatment drugs. When given take-home doses of methadone for the weekend, he would sell them for heroin.

    "When I'm on Vivitrol, I can't get high," he said. The drug has no street value or abuse potential.

    "You couldn't design something better for the criminal justice system," said David Farabee of the University of California at Los Angeles, who leads a Vivitrol study in a New Mexico jail. "There's been pushback with other medications, people saying, 'We're just changing one drug for another.' That argument goes out the window when you're talking about a blocker" like Vivitrol.

    Driver Flees Traffic Stop, Dragging Police Officer

    [NATL-DFW] Driver Flees Traffic Stop, Dragging Police Officer

    Body camera footage shows a Florida police officer being dragged by a driver attempting to flee a traffic stop.

    Police said Frank Wetzel, 61, was pulled over after blowing through a stop sign. Police said he started fidgeting with something next to him, making the officer suspicious. He was allegedly later found with a machete and handgun.

    (Published Monday, April 24, 2017)

    Prison systems in Illinois, Vermont, Wyoming and Wisconsin are trying the drug on a small scale. Michigan is offering Vivitrol to parolees who commit small crimes, if addiction is the reason for their new offense. The federal Bureau of Prisons ran a field trial in Texas and plans to expand the program to the Northeast next year. The drug's manufacturer hopes prisons will be the gateway to a larger market.

    Also known as extended-release naltrexone, the medication won Food and Drug Administration approval for alcohol dependence in 2006 and in 2010 to prevent relapse in post-detox opioid users.

    The evidence for giving Vivitrol to inmates is thin but promising.

    In the biggest study, sponsored by the National Institute on Drug Abuse, about 300 offenders — most of them heroin users on probation or parole — were randomly assigned to receive either Vivitrol or brief counseling and referral to a treatment program.

    After six months, the Vivitrol group had a lower rate of relapse, 43 percent compared with 64 percent. A year after treatment stopped, there had been no overdoses in the Vivitrol group and seven overdoses, including three deaths, in the other group. The results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.

    Yet addiction is stubborn. When the injections stopped, many in the study relapsed. A year later, relapse rates looked the same in the two groups.

    "It does suggest six months wasn't enough," said Lee, the lead author.

    T.J. Voller was a Vivitrol success story — until he wasn't. After Vivitrol was approved by the FDA, Voller talked about getting the shot with The Associated Press and Dr. Sanjay Gupta in a CNN segment. The 30-year-old was back at work and seemed proud of his recovery. But after 10 months on Vivitrol, he died of a heroin overdose.

    Flight Attendant's Behavior Questioned Following Altercation

    [NATL-BAY] Flight Attendant's Behavior Questioned Following Altercation

    One day after an American Airlines flight attendant became entangled in an altercation with passengers, his employer is investigating whether or not he was out of line. Thom Jensen reports.

    (Published Sunday, April 23, 2017)

    "He was alone for the weekend and picked up that needle one last time," said his mother, Kathi Voller of Raynham, Massachusetts.

    Advocates argue that inmates have a constitutional right to all FDA-approved addiction medications throughout their incarceration.

    "Treatment should be offered from the moment they are brought into the system," said Sally Friedman, legal director of the New York-based Legal Action Center, which is looking for a test case to bring to court.

    Physicians have learned to be cautious about pharmaceutical company marketing, said Andrew Kolodny, senior scientist at the Heller School for Social Policy and Management at Brandeis University.

    Drive-Thru Pot Dispensary Opens in Colorado

    [NATL] Drive-Thru Pot Dispensary Opens in Colorado

    When you think of a drive-thru, fast food probably comes to mind. But what about marijuana? Tumbleweed Express Drive-Thru in Parachute, Colorado, is the first of its kind. After nearly a year of preparation, the drive-thru pot shop opened for business on 4/20. 

    "Their timing couldn't have been better in my opinion, I mean everybody wants to celebrate," said Kyle Steele, a customer at the drive-thru.

    (Published Friday, April 21, 2017)

    Not so for criminal justice officials, who may be too trusting, Kolodny said.

    "When the drug company sends someone in to give them a talk and buy them pizza, they think they're getting a scientific lecture," he said.

    Alkermes spokeswoman Jennifer Snyder said the company's sales team helps educate corrections staff and community care providers only after they have shown interest in Vivitrol.

    There's widespread agreement that counseling, support groups and treatment for underlying problems such as depression are crucial for Vivitrol patients, said Dr. Joseph Garbely of Pennsylvania-based Caron Treatment Centers, which supports medication-assisted treatment and prefers Vivitrol.

    Protester, Official React to Arkansas Execution

    [NATL] Protester, Official React to Arkansas Execution

    Just before midnight Thursday, Arkansas announced it had executed death row inmate Ledell Lee. He is the first of four inmates scheduled to die before the end of the month when a crucial lethal injection drug is set to expire. A protester and a spokesperson for the governor reacted to the controversial execution.

    (Published Friday, April 21, 2017)

    "The disease of addiction is a cunning, baffling and powerful one," Garbely said. "And you need all hands on deck."